Gyre Therapeutics (GYRE) Share-based Compensation (2010 - 2026)
Gyre Therapeutics (GYRE) reported Share-based Compensation of $2.6 million for Q1 2026, up 409.47% year-over-year from $507000.0 in Q1 2025, and down 43.81% quarter-over-quarter from $4.6 million in Q4 2025.
Gyre Therapeutics (GYRE) Share-based Compensation (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Share-based Compensation data on file, last reported at $2.6 million in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $2.6 million, up 409.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 million (up 595.78% YoY), and the FY2025 annual result was $7.2 million, up 761.25% from the prior year.
- Share-based Compensation retreated to $2.6 million in Q1 2026 per GYRE's latest filing, from $4.6 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $12.3 million in Q4 2022 and troughed at $11000.0 in Q1 2024.
- A 5-year average of $1.8 million and a median of $507000.0 in 2025 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 94.76% in 2024, then soared 5562.5% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $12.3 million in 2022, then slumped by 43.95% to $6.9 million in 2023, then sank by 91.76% to $567000.0 in 2024, then soared by 710.76% to $4.6 million in 2025, then tumbled by 43.81% to $2.6 million in 2026.
- Business Quant data shows GYRE's Share-based Compensation at $2.6 million in Q1 2026, $4.6 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.58 Mn |
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 906,000.00 |
| Jun 30, 2025 | 906,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Dec 31, 2024 | 567,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Dec 31, 2023 | 6.88 Mn |
| Dec 31, 2023 | 6.88 Mn |